Merck continues it’s stellar string of “achievements” by creating a fraudulent peer-review journal to publish data that casts a favorable light on Fosamax and other drugs. I’m not surprised at this course off action from Merck, a company that hasn’t had a blockbuster drug in years. I am more furious at Elsevier, a respected academic journal publisher, that did NOT exercise due diligence and placed their own integrity on the line for payola.
The question I always have when these scandals break is how many yesmen and yeswomen in both companies did it take to let this fly? Seriously who with commoncents thought this was a good idea.
mikalfm 